10x Genomics, Inc. (TXG)

10x Genomics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-43.54	-182.63	-255.1	-166	-58.22
Depreciation & Amortization	43.82	43.71	43.62	33.01	28.25
Stock-Based Compensation	109.12	140.75	166.95	136.85	95.96
Other Adjustments	1.72	3.58	11.99	1.96	0.08
Change in Receivables	6.44	26.95	-10.61	-18.95	-34.04
Changes in Inventories	27.95	-9.78	7.87	-21.19	-30.13
Changes in Accounts Payable	-2.13	-3.35	-6.02	5.86	11.08
Changes in Accrued Expenses	2.49	-9.08	25.66	4.45	-28.71
Changes in Unearned Revenue	0.75	11.21	10.93	3.35	1.54
Changes in Other Operating Activities	-10.57	-14.69	-10.49	-12.94	-7.18
Operating Cash Flow	136.05	6.66	-15.2	-33.61	-21.37
Operating Cash Flow Growth	1941.57%	-	-	-	-
Capital Expenditures	-5.94	-12.39	-48.6	-131.66	-101.28
Purchases of Intangible Assets	-	-1	-0.92	-	-
Purchases of Investments	-123.44	-48.88	-	-282.87	-
Proceeds from Sale of Investments	125.2	29.64	183.02	67.65	-
Payments for Business Acquisitions	-9.27	-	-	-4	-5.45
Investing Cash Flow	-13.44	-32.63	133.49	-350.89	-106.73
Issuance of Common Stock	6.8	10.91	19.48	21.23	40.33
Net Common Stock Issued (Repurchased)	6.8	10.91	19.48	21.23	40.33
Other Financing Activities	-	-	-5.81	-5.41	-5.03
Financing Cash Flow	6.8	10.91	13.67	15.82	35.3
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.48	-0.16	-0.03	-0.04	0.23
Net Cash Flow	129.9	-15.22	131.93	-368.72	-92.57
Free Cash Flow	130.12	-5.73	-63.8	-165.27	-122.65
FCF Margin	20.24%	-0.94%	-10.31%	-32.00%	-25.01%
Free Cash Flow Per Share	1.04	-0.05	-0.54	-1.45	-1.11
Levered Free Cash Flow	12.84	-177.01	-232.13	-285.12	-184.65
Unlevered Free Cash Flow	-10.16	-194.34	-249.11	-291.25	-183.07

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q